Davis Joseph wins international award for revolutionary cancer treatment discovery

The Sustainability through Science and Technology Summit 2025 (SIPS 2025), celebrating its 21st edition in Cebu, Philippines, from 17–20 November 2025, presented the 2025 Ciechanover International Biology Award to Davis Joseph. This prestigious honor recognizes his revolutionary discovery regarding cancer treatments that function independently of the organs in which the tumors develop.

Davis Joseph's work has, for the first time, overturned two-century-old paradigms:

1. The Organ-Specific Paradigm: Traditionally, cancers have been treated based on the organs where they originate. Since cancer was first identified in the human body, a universal "pan-organ" denominator had never been proposed.
2. The Isolationist Paradigm: Cancer biochemistry has historically been studied in isolation-one pathway at a time-without accounting for the complex interactions between proteins and regulatory RNAs that characterize a living organism.

In this breakthrough work, Davis Joseph identified three universal cancer types based on the malfunction of specific proteins and regulatory RNAs:
• Type 1: Cells lacking a functional p14ARF or p53 gene.
• Type 2: Cells lacking a functional DINO lncRNA.
• Type 3: Cells exhibiting abnormally high MDM2 protein activity.

By developing a unified therapeutic theory, Joseph has identified novel targets for treating cancer regardless of the primary organ. This paves the way for a revolutionary, organ-agnostic approach to oncology.

Furthermore, Joseph has developed the first universal apoptosis network flowsheet, comprising approximately 100 pathways (80% activation and 20% inhibition). This was achieved through a critical analysis of 174 scientific publications, mapping the intricate interactions between proteins and regulatory RNAs.

This discovery exemplifies Sustainable Medicine under the FLOGEN Sustainability Framework by fulfilling three key criteria:

1. Social Development: Enhancing human quality of life through better health outcomes.
2. Economic Development: Reducing medical costs by creating a unified treatment applicable to numerous cancers.
3. Environmental Protection: Minimizing the resources required to produce specialized medicines for different organ-specific cancers.

Joseph presented this major discovery for the first time as a plenary lecture at SIPS 2025 and published it in the SIPS 2025 proceedings. Subsequently, he published it with his coauthors-Kongoli, You, and Inufusa-in Nature Portfolio's Cell Death Discovery, a Q1 journal with an Impact Factor of 7.0 (https://www.nature.com/articles/s41420-026-03066-2). The paper set a record with over 2,000 accesses within its first two weeks.

"When I read Davis's papers, I thought he could receive the Nobel Prize by 35; but when I saw his presentation, I think he could receive it by 28," noted Professor Aaron Ciechanover, 2004 Nobel Laureate in Chemistry.

The Ciechanover International Biology Award, named in honor of Professor Ciechanover and given yearly since 2022, was personally presented to Davis Joseph by Professor Ciechanover himself during the SIPS 2025 Gala and Award Ceremony on November 19, 2025, at the Dusit Thani Mactan Cebu Resort in the Philippines. Photos and videos of the ceremony and interviews are available here: https://www.flogen.org/?p=182&bio=2025_Davis_Joseph

A Prolific Research Trajectory: Three Discoveries in 1.5 Years

This oncology breakthrough marks Davis Joseph's third major discovery in just 18 months:

1. The Davis Joseph Principle (Neurobiology): The first discovery identified the fundamental neurobiological mechanism of 4E-BP2 protein deamidation. Joseph determined that axons-the cable-like structures of brain cells-are the primary site of deamidation in the brain. Described as "Nobel-worthy" by Dr. Harvey Alter and Dr. Gregg Semenza (2020 and 2019 Nobel Laureates), this work was published in the International Journal of Molecular Sciences (IJMS). (https://www.mdpi.com/1422-0067/25/22/12268). It achieved a world record for a single-author publication with approximately 15,000 accesses in one year and ranks in the top 5% (specifically the top 2.6%) of over 32 million research outputs tracked by Altmetric.

2. The Common Master Switch for Neurodegeneration: The second discovery addressed a historic gap in Alzheimer's and Parkinson's research by identifying a common master switch. This mechanism offers a potential unified cure for various brain-related diseases despite their unique pathologies. Published in IJMS on April 27, 2025 (https://www.mdpi.com/1422-0067/26/9/4143), it has been accessed 12,000 times in less than a year, ranking in the top 10% (5.2%) of all research outputs worldwide. Both discoveries were covered by more than 1000 media outlets worldwide.